RxDoctor Payments Data

Vachaspathi Palakodeti, MD

Cardiovascular Disease · Imperial, CANPI 1649224387

Payments from drug & device makers

$401,219in general payments, 2019–2025

Across 22 payments — averaging $18,237 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vektor Medical Inc.$400K
  • Boston Scientific$272
  • Amgen$272
  • Novartis$259
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$175
  • AstraZeneca$112
  • plus $129 from 5 others

What the payments were for

  • Food & beverage$1,20599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$401,219 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$2,911,350
Medicare patients
3,256
Services billed
38,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban975$989,398
EntrestoSacubitril/Valsartan1,019$969,080
XareltoRivaroxaban655$633,221
JardianceEmpagliflozin374$358,419
FarxigaDapagliflozin Propanediol135$131,967
Repatha SyringeEvolocumab69$52,211
Repatha SureclickEvolocumab71$47,294
DapagliflozinDapagliflozin Propanediol46$41,622
BrilintaTicagrelor51$34,865
Metoprolol Succinate2,202$34,442
VascepaIcosapent Ethyl51$24,526
MultaqDronedarone Hcl27$21,161
InpefaSotagliflozin29$18,293
OzempicSemaglutide19$17,131
Icosapent Ethyl46$14,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$259$969,0801,019 claims
AstraZenecaFarxiga, Brilinta$112$166,832186 claims
AmgenCorlanor$272$13,26618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Imperial

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →